Lexicon Pharmaceuticals Q4 EPS $(0.20) Beats $(0.22) Estimate, Cash Position $170M
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q4 earnings with losses of $(0.20) per share, surpassing the consensus estimate of $(0.22) by 9.09%. This represents a 25% increase in losses compared to the same period last year. The company's cash position stands at $170M.
March 11, 2024 | 11:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lexicon Pharmaceuticals reported better-than-expected Q4 losses and has a strong cash position of $170M.
Beating earnings estimates typically has a positive impact on stock price as it indicates the company is performing better than analysts expected. The strong cash position further supports the company's financial stability, which can be viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100